Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-20-109

Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)

Closed on January 5, 2022.

Posted
February 6, 2020
Close date
January 5, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $264,507 in first-year total cost, median $264,507.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 BST-R (10)]1

Most frequent institutions

  1. 3P BIOTECHNOLOGIES, INC.1
Competing awards under PAR-20-109 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022Engineered Exosomes for Targeted Delivery of the CRISPR/Cas9 Genome-editor1R41OD031942-01A1GUPTA, RAMESH CSPENCER, WENDY A3P BIOTECHNOLOGIES, INC., KY$264,507ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-20-109: Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed) | ScienceDex | ConductScience